🔎 Trials Near Me

Почетна › Рак простате › Тексас

Kliničke studije za Рак простате u državi Тексас

113 studija za Рак простате traži učesnike na lokacijama u državi Тексас.

Gradovi u državi Тексас

Zvanični tekst studije (na engleskom)

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 13. 11. 2026. · NCT04423211

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Мушкарци · Ажурирано 12. 11. 2026. · NCT05691465

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 12. 11. 2026. · NCT04221542

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03866382

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Мушкарци · Ажурирано 12. 11. 2026. · NCT05454488

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • Urology Partners of North Texas (UPNT), Arlington
Тражи се учесник
Узраст 18 и старији · Мушкарци · Ажурирано 12. 11. 2026. · NCT06511141

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT04557449

WATER IV PCa (AS Sub-study)

  • Midtown Urology, Austin
  • Urology Austin, Austin
  • Urology Clinics of North Texas, Dallas
Тражи се учесник
Узраст 45 и старији · Мушкарци · Ажурирано 6. 11. 2026. · NCT07650448

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

  • Urology Austin, Austin
Тражи се учесникФаза 4
Узраст 18 и старији · Мушкарци · Ажурирано 5. 11. 2026. · NCT07569926

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Texas Oncology - DFW (Sammons CC), Dallas
  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07114601

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06632977

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Urology Clinics Of North Texas, Dallas
  • Urology Partners of North Texas (UPNT), Fort Worth
  • Houston Metro Urology (HMU), Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT07723248

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06066437

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  • MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT06095089

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • Covenant Medical Center-Lakeside, Lubbock
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT07200830

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT06931340

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  • NEXT Oncology, Austin
  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT06800313

A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer

  • Renovatio Clinical 1, El Paso
  • Renovatio Clinical, The Woodlands
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT07906717

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 3. 11. 2026. · NCT05800665

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07887971

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Мушкарци · Ажурирано 2. 11. 2026. · NCT05873192

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • Parkland Health & Hospital System ( Site 0069), Dallas
  • UT Southwestern Medical Center ( Site 0039), Dallas
  • University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 30. 10. 2026. · NCT06925737

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • Mary Crowley Cancer Research, Dallas
  • University of Texas Southwestern Medical Center, Dallas
  • Houston Methodist Hospital, Houston
Тражи се учесникФаза 1
Узраст од 18 до 100 · Мушкарци · Ажурирано 29. 10. 2026. · NCT05519449

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  • START, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07288359

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 27. 10. 2026. · NCT05997615

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Мушкарци · Ажурирано 26. 10. 2026. · NCT05593497

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  • Mary Crowley Cancer Research, Dallas
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 23. 10. 2026. · NCT07570979

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • UT MD Anderson - The Woodlands, Conroe
  • Brooke Army Medical Center, Fort Sam Houston
  • UT MD Anderson Cancer Center, Houston
  • и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 23. 10. 2026. · NCT05946213

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  • Research Site, Houston
Тражи се учесникФаза 1/2
Узраст од 18 до 130 · Мушкарци · Ажурирано 22. 10. 2026. · NCT07181161

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 135, Austin
  • Research Site 120, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  • USA Clinical Trials, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Мушкарци · Ажурирано 20. 10. 2026. · NCT07103018

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • Texas Oncology - Central/South Texas ( Site 8003), Austin
  • Texas Oncology - DFW ( Site 8001), Dallas
  • Texas Oncology - Gulf Coast ( Site 8002), Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06136650

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • The Center for Cancer and Blood Disorders, Arlington
  • University of Texas Southwestern Medical Center, Dallas
  • Renovatio Clinical, Houston
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 20. 10. 2026. · NCT07213674

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 19. 10. 2026. · NCT07611110

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • MD Anderson Cancer Center, Houston
  • NEXT Oncology, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06239194

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  • Research Site, Austin
  • Research Site, Dallas
  • Research Site, Fort Worth
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Мушкарци · Ажурирано 15. 10. 2026. · NCT07711002

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.